Steven Zeig

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

Anthony J. Bleyer, Steven K. Burke, Maureen Dillon et al. · American Journal of Kidney Diseases · 1999 · 278 citations

Medicine, Nephrology, Pharmacotherapy +16

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Robert Provenzano, Anatole Besarab, Steven Charles Wright et al. · American Journal of Kidney Diseases · 2016 · 256 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis

Julia B. Lewis, Mohammed Sika, Mark J. Koury et al. · Journal of the American Society of Nephrology · 2014 · 191 citations · Full text

Medicine, Nephrology, Nutrition +17